Eisai Submits New Drug Application for Subcutaneous Formulation of LEQEMBI for the Treatment of Early Alzheimers Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in…
Altai Provides Update on Quebec Litigation
September 05, 2025 18:39 ET Â | Source: Altai Resources Inc. TORONTO, Sept.…
New APOE4 App Uses AI Digital Twins to Help 25% of Population at High Alzheimer’s Risk
Phoenix platform matches users with genetically similar people to predict which interventions…